BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 1.11.1994

Prospective Grant of Co-Exclusive License; Vector With Multiple Target Response Elements Affecting Gene Expression

This notice is in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a co-exclusive world-wide license to practice the invention embodied in U.S. Patent Application SN 07/596,299 (CIP of 07/467,497) entitled ``Vector With Multiple Target Response Elements Affecting Gene Expression'' to Targeted Genetics Corporation, of Seattle, Washington. The patent rights in this invention have been assigned to the United States of America. The prospective license will be royalty-bearing, will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7, and will be co-exclusive with one other party, Genetic Therapy, Inc. It is anticipated that this license will be limited to the field of use of gene therapy treatment for Acquired Immunodeficiency Syndrome (AIDS). Publication of this notice should be considered a modification of an earlier notice ``Prospective Grant Of Exclusive License: Vectors For Gene Therapy Treatment Of AIDS'' (Vol. 57, No. 169, Monday, August 31, 1992, page 39405). This prospective co-exclusive license may be granted unless, within 60 day

Source: Federal Register — Health and Human ServicesOpen original release →